维生素D3补充降低起始抗逆转录病毒治疗的HIV感染坦桑尼亚成人肺结核发病率和死亡率的效果:随机对照试验研究方案
ToV4是一项在坦桑尼亚达累斯萨拉姆开展的个体随机、双盲、安慰剂对照试验,纳入4000名维生素D水平低(25-羟维生素D<30 ng/mL)且起始抗逆转录病毒治疗的HIV感染成人。试验旨在确定维生素D3补充方案对比安慰剂对死亡率和肺结核发病率的影响,主要安全性结局为高钙血症。
要点
- 纳入4000名25-羟维生素D<30 ng/mL的HIV感染成人,随机接受维生素D3或安慰剂。
- 维生素D3方案:随机化时直接观察下口服50000 IU,每周1次共3周(4剂),随后每日口服2000 IU至ART起始后1年。
- 主要结局为死亡率和肺结核发病率,主要安全性结局为高钙血症。
核心结论
- ToV4将提供维生素D3补充对起始ART的HIV感染坦桑尼亚成人肺结核发病率和死亡率影响的因果证据。
- 该试验还将揭示是否应在HIV未感染人群中开展维生素D3补充预防肺结核的试验。
研究设计与样本
- 个体随机、双盲、安慰剂对照试验(ToV4),在坦桑尼亚达累斯萨拉姆开展。
- 纳入4000名维生素D水平低(25-羟维生素D<30 ng/mL)且起始ART的HIV感染成人。
关键数值与推荐
- 维生素D3方案:随机化时直接观察下口服50000 IU,每周1次共3周(4剂),随后每日口服2000 IU至ART起始后1年。
- 主要结局为死亡率和肺结核发病率,主要安全性结局为高钙血症。
- 次要结局包括CD4 T细胞重建、非结核合并症发病率、BMI、抑郁和焦虑、体力活动、骨骼健康和免疫学生物标志物。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HIV-infected adults initiating antiretroviral therapy (ART) in sub-Saharan Africa continue to experience high rates of morbidity and mortality during the initial months of treatment. Observational studies in high-income and resource-limited settings indicate that HIV-infected adults with low vitamin D levels may be at increased risk of mortality, HIV disease progression, and incidence of pulmonary tuberculosis (TB). As a result, vitamin D3 supplementation may improve survival and treatment outcomes for HIV-infected adults initiating ART. METHODS/DESIGN: The Trial of Vitamins-4 (ToV4) is an individually randomized, double-blind, placebo-controlled trial of vitamin D3 (cholecalciferol) supplementation conducted among 4000 HIV-infected adults with low vitamin D levels [25-hydroxyvitamin D (25(OH)D) <30 ng/mL] initiating ART in Dar es Salaam, Tanzania. The two primary aims of the trial are to determine the effect of a vitamin D3 supplementation regimen on incidence of (1) mortality and (2) pulmonary TB as compared to a matching placebo regimen. The primary safety outcome of the study is incident hypercalcemia. The investigational vitamin D3 regimen consists of oral supplements containing 50,000 IU vitamin D3 taken under direct observation at randomization and once a week for 3 weeks (four doses) followed by daily oral supplements containing 2000 IU vitamin D3 taken at home from the fourth week until trial discharge at 1 year post ART initiation. Trial participants are followed up at weekly clinic visits during the first month of ART and at monthly clinic visits thereafter until trial discharge at 1 year post ART initiation. Secondary aims of the trial are to examine the effect of the vitamin D3 regimen on CD4 T cell reconstitution, incidence of non-TB comorbidities, body mass index (BMI), depression and anxiety, physical activity, bone health, and immunologic biomarkers. DISCUSSION: The ToV4 will provide causal evidence on the effect of vitamin D3 supplementation on incidence of pulmonary TB and mortality among HIV-infected Tanzanian adults initiating ART. The trial will also give insight to whether vitamin D3 supplementation trials for the prevention of pulmonary TB should be pursued in HIV-uninfected populations. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01798680 . Registered on 21 February 2013.
引用
- Sudfeld CR, Mugusi F, Aboud S, et al. Efficacy of vitamin D3 supplementation in reducing incidence of pulmonary tuberculosis and mortality among HIV-infected Tanzanian adults initiating antiretroviral therapy: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28183335. doi:10.1186/s13063-017-1819-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。